Cardlytics (CDLX) EBITDA (2017 - 2026)

Cardlytics has reported EBITDA for 10 years, with the latest figure at -$8.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 25.56% year-over-year to -$8.3 million; the trailing twelve-month figure through Mar 2026 stood at -$96.0 million (up 47.76% YoY), and the FY2025 full-year result was -$101.8 million, up 47.92% from the prior year.
• EBITDA for Q1 2026 stood at -$8.3 million, down from -$6.1 million in the prior quarter.
• The five-year high for EBITDA was $35.7 million in Q1 2022, with the low at -$382.6 million in Q4 2022.
• Historically, EBITDA has averaged -$52.7 million across 5 years, with a median of -$15.8 million in 2024.
• The largest YoY upside for EBITDA was 260.84% in 2022 against a maximum downside of 2231.86% in 2022.
• Cardlytics' EBITDA stood at -$382.6 million in 2022, then jumped by 73.1% to -$102.9 million in 2023, then soared by 91.92% to -$8.3 million in 2024, then grew by 26.69% to -$6.1 million in 2025, then sank by 35.75% to -$8.3 million in 2026.
• The last three EBITDA figures came in at -$8.3 million (Q1 2026), -$6.1 million (Q4 2025), and -$68.9 million (Q3 2025), per Business Quant data.